Merck & Company Inc (MRK)vsUniqure NV (QURE)
MRK
Merck & Company Inc
$146.35
+3.85%
HEALTHCARE · Cap: $360.08B
QURE
Uniqure NV
$24.97
+2.84%
HEALTHCARE · Cap: $1.56B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 356418% more annual revenue ($66.57B vs $18.67M). MRK leads profitability with a 4.8% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 36/100 (F).
MRK
Hold36
out of 100
Grade: F
QURE
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$83.64
Current Price
$146.35
$62.71 premium
Intrinsic value data unavailable for QURE.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Conservative balance sheet, low leverage
Areas to Watch
Trading at 8.6x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -228.2% — below average capital efficiency
Earnings declined 18.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : QURE
The strongest argument for QURE centers on Debt/Equity. Revenue growth of 11.0% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 115.8x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : QURE
The primary concerns for QURE are Market Cap, Profit Margin, Return on Equity.
Key Dynamics to Monitor
QURE carries more volatility with a beta of 1.06 — expect wider price swings.
QURE is growing revenue faster at 11.0% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (36/100 vs 24/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Uniqure NV
HEALTHCARE · BIOTECHNOLOGY · USA
uniQure NV, a gene therapy company, is dedicated to developing treatments for patients suffering from genetic and other devastating diseases. The company is headquartered in Amsterdam, the Netherlands.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?